These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 33418504)

  • 21. Onset of subacute cutaneous lupus erythematosus after the initiation of immune checkpoint inhibitor therapy of cancer.
    Gambichler T; Doerler M; Scheel CH
    Lupus; 2021 Mar; 30(3):531-533. PubMed ID: 33407044
    [No Abstract]   [Full Text] [Related]  

  • 22. Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience.
    Fortes BH; Liou H; Dalvin LA
    Br J Ophthalmol; 2021 Sep; 105(9):1263-1271. PubMed ID: 32830124
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune Checkpoint Inhibition in Prostate Cancer.
    Nicholson LT; Fong L
    Trends Cancer; 2020 Mar; 6(3):174-177. PubMed ID: 32101720
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant Immunotherapy for Locally Advanced Melanoma.
    Pelster MS; Amaria RN
    Curr Treat Options Oncol; 2020 Feb; 21(2):10. PubMed ID: 32025932
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased risk of immune checkpoint inhibitor-induced type 1 diabetes mellitus with the new approved 6-week scheme of pembrolizumab in patients with melanoma?
    Kähler KC; Kosova K; Bohne AS; Schreiber S; Hauschild A
    Eur J Cancer; 2020 Oct; 138():169-171. PubMed ID: 32890812
    [No Abstract]   [Full Text] [Related]  

  • 26. The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.
    van Dijk N; Funt SA; Blank CU; Powles T; Rosenberg JE; van der Heijden MS
    Eur Urol; 2019 Mar; 75(3):435-444. PubMed ID: 30274701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibiotic administration shortly before or after immunotherapy initiation is correlated with poor prognosis in solid cancer patients: An up-to-date systematic review and meta-analysis.
    Yang M; Wang Y; Yuan M; Tao M; Kong C; Li H; Tong J; Zhu H; Yan X
    Int Immunopharmacol; 2020 Nov; 88():106876. PubMed ID: 32799113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk Factors for Immunotherapy-related Adverse Events (IrAE) in Patients Treated With Immune Checkpoint Inhibitors.
    Hadfield MJ; Mistry H; Pelcovits A; Bansal R; Andrea S; Chergui A; Ramphal K; Austin M; Khurshid H
    Am J Clin Oncol; 2023 Apr; 46(4):183-184. PubMed ID: 36959209
    [No Abstract]   [Full Text] [Related]  

  • 29. Dendritic Cells and Their Role in Immunotherapy.
    Gardner A; de Mingo Pulido Á; Ruffell B
    Front Immunol; 2020; 11():924. PubMed ID: 32508825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune checkpoint inhibitors: a promising anticancer therapy.
    Singh S; Hassan D; Aldawsari HM; Molugulu N; Shukla R; Kesharwani P
    Drug Discov Today; 2020 Jan; 25(1):223-229. PubMed ID: 31738877
    [TBL] [Abstract][Full Text] [Related]  

  • 31. On OX40 and PD-1 Combination: Why Should OX40 Be First in Sequence?
    Colombo MP
    Clin Cancer Res; 2017 Oct; 23(20):5999-6001. PubMed ID: 29030331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19.
    Goldstein DA; Ratain MJ; Saltz LB
    JAMA Oncol; 2020 Nov; 6(11):1694-1695. PubMed ID: 32459313
    [No Abstract]   [Full Text] [Related]  

  • 33. Unleashing the power of immunotherapy and targeted therapy combinations: Advancing cancer care or discovering unknown toxicities?
    Przybylski DJ; Bergsbaken JJ; Piccolo JK
    J Oncol Pharm Pract; 2021 Jun; 27(4):930-938. PubMed ID: 33406979
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities.
    Pauken KE; Dougan M; Rose NR; Lichtman AH; Sharpe AH
    Trends Immunol; 2019 Jun; 40(6):511-523. PubMed ID: 31053497
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy.
    Schweizer C; Schubert P; Rutzner S; Eckstein M; Haderlein M; Lettmaier S; Semrau S; Gostian AO; Frey B; Gaipl US; Zhou JG; Fietkau R; Hecht M
    Eur J Cancer; 2020 Nov; 140():55-62. PubMed ID: 33045663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune checkpoint inhibitors: The linchpins of modern immunotherapy.
    Wilky BA
    Immunol Rev; 2019 Jul; 290(1):6-23. PubMed ID: 31355494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Encephalitis in a Patient With Melanoma Treated With Immune Checkpoint Inhibitors: Case Presentation and Review of the Literature.
    Gkoufa A; Gogas H; Diamantopoulos PT; Ziogas DC; Psichogiou M
    J Immunother; 2020 Sep; 43(7):224-229. PubMed ID: 32554976
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real Impact of Novel Immunotherapy Drugs in Cancer. The Experience of 10 Last Years.
    Koulouris A; Tsagkaris C; Nikolaou M
    Toxins (Basel); 2021 Feb; 13(2):. PubMed ID: 33672017
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of immune-checkpoint inhibitors in lung cancer.
    Jain P; Jain C; Velcheti V
    Ther Adv Respir Dis; 2018; 12():1753465817750075. PubMed ID: 29385894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Why are immune adverse events so common with checkpoint inhibitor therapy?
    Lyubchenko T; Leung DYM; Goleva E
    Ann Allergy Asthma Immunol; 2021 Jun; 126(6):608-610. PubMed ID: 33774187
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.